Aminoglycoside susceptibility | No of isolates | No of isolates / (cumulative % of isolates) inhibited at plazomicin MIC (mg/L) of a | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
≤0.125 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | ≥64d | ||
Amikacin Sb | 54 | 5 (9.3) | 23 (51.9) | 11 (72.2) | 9 (88.9) | 1 (90.7) | 5 (100) | 0 (−) | 0 (−) | 0 (−) | 0 (−) |
Amikacin NSc | 246 | 3 (1.2) | 55 (23.6) | 56 (46.3) | 74 (76.4) | 24 (86.2) | 8 (89.4) | 3 (90.7) | 0 (90.7) | 0 (90.7) | 23 (100) |
Amikacin NS (excluding RMT positive isolates) | 223 | 3 (1.3) | 55 (26.0) | 56 (51.1) | 74 (84.3) | 24 (95.1) | 8 (98.7) | 3 (100) | 0 (−) | 0 (−) | 0 (−) |
Gentamicin S | 129 | 3 (2.3) | 52 (42.6) | 41 (74.4) | 24 (93.0) | 5 (96.9) | 4 (100) | 0 (−) | 0 (−) | 0 (−) | 0 (−) |
Gentamicin NS | 171 | 5 (2.9) | 26 (18.1) | 26 (33.3) | 59 (67.8) | 20 (79.5) | 9 (84.8) | 3 (86.5) | 0 (86.5) | 0 (86.5) | 23 (100) |
Gentamicin NS (excluding RMT positive isolates) | 148 | 5 (3.4) | 26 (20.9) | 26 (38.5) | 59 (78.4) | 20 (91.9) | 9 (97.8) | 3 (100) | 0 (−) | 0 (−) | 0 (−) |
Amikacin NS/Gentamicin NS | 154 | 2 (1.3) | 15 (11.0) | 25 (27.3) | 58 (64.9) | 20 (77.9) | 8 (83.1) | 3 (85.1) | 0 (85.1) | 0 (85.1) | 23 (100) |
Amikacin NS/Gentamicin NS (excluding RMT positive isolates) | 131 | 2 (1.5) | 15 (13.0) | 25 (32.1) | 58 (76.3) | 20 (91.6) | 8 (97.7) | 3 (100) | 0 (−) | 0 (−) | 0 (−) |
Amikacin NS/Gentamicin S | 92 | 1 (1.1) | 40 (44.6) | 31 (78.3) | 16 (95.7) | 4 (100) | 0 (−) | 0 (−) | 0 (−) | 0 (−) | 0 (−) |
Amikacin S/Gentamicin NS | 17 | 3 (17.6) | 11 (82.4) | 1 (88.2) | 1 (94.1) | 0 (94.1) | 1 (100) | 0 (−) | 0 (−) | 0 (−) | 0 (−) |
Amikacin S/Gentamicin S | 28 | 1 (3.6) | 8 (32.1) | 6 (53.6) | 8 (82.1) | 1 (85.7) | 4 (100) | 0 (−) | 0 (−) | 0 (−) | 0 (−) |
All isolates excluding RMT positives | 277 | 8 (2.9) | 78 (31.0) | 67 (55.2) | 83 (85.2) | 25 (94.2) | 13 (98.9) | 3 (100) | 0 (−) | 0 (−) | 0 (−) |